COL25A1 and METAP1D DNA methylation are promising liquid biopsy epigenetic biomarkers of colorectal cancer using digital PCR.
Fiche publication
Date publication
octobre 2024
Journal
Clinical epigenetics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Pr GUITTAUT Michaël, Mr MONNIEN Franck, Dr HERVOUET Eric, Dr PEIXOTO Paul, Dr VIENOT Angélique, Pr FEUGEAS Jean-Paul, Dr SELMANI Zohair, Dr MOLIMARD Chloé
Tous les auteurs :
Overs A, Peixoto P, Hervouet E, Molimard C, Monnien F, Durand J, Guittaut M, Vienot A, Viot J, Herfs M, Borg C, Feugeas JP, Selmani Z
Lien Pubmed
Résumé
Colorectal cancer is a public health issue and was the third leading cause of cancer-related death worldwide in 2022. Early diagnosis can improve prognosis, making screening a central part of colorectal cancer management. Blood-based screening, diagnosis and follow-up of colorectal cancer patients are possible with the study of cell-free circulating tumor DNA. This study aimed to identify novel DNA methylation biomarkers of colorectal cancer that can be used for the follow-up of patients with colorectal cancer.
Mots clés
Biomarker, COL25A1, Circulating tumor DNA, Colorectal cancer, DNA methylation, Digital PCR, Liquid biopsy, METAP1D
Référence
Clin Epigenetics. 2024 10 18;16(1):146